Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 21, Issue 8, 2009, Pages 976-983

  Springer, Sandra A ^a   Chen, Shu ^a   Altice, Frederick ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; CD4 lymphocyte count; CES D; DAART; Depression; Directly administered antiretroviral therapy; HIV 1 RNA; HIV AIDS; Injection drug users; Substance abuse

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CASE MANAGEMENT; CD4 LYMPHOCYTE COUNT; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTLY ADMINISTERED ANTIRETROVIRAL THERAPY; DISEASE SEVERITY; EMPLOYMENT; FEMALE; FOLLOW UP; GENDER; HOMELESSNESS; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH SERVICE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SOCIAL ASPECT; SOCIAL SUPPORT; SYMPTOM; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; DEPRESSIVE DISORDER; DIRECTLY OBSERVED THERAPY; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 70450179814     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120802657555     Document Type: Article

References (33)

1. Altice, F.L., Maru, D.S., Bruce, R.D., Springer, S.A., & Friedland, G.H. (2007). Superiority ofdirectly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clinical Infectious Disease, 45(6), 770-778.
2. Altice, F.L., Mezger, J.A., Hodges, J., Bruce, R.D., Marinovich, A., Walton, M., et al. (2004). Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clinical Infectious Disease, 38(Suppl. 5), 376-387.
3. Bangsberg, D.R., Moss, A., & Deeks, S. (2004). Paradoxes ofadherence and drug resistance to HIV antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 53, 696-699.
4. Berger-Greenstein, J.A., Cuevas, C.A., Brady, S.M., Trezza, G., Richardson, M.A., & Keane, T.M. (2007). Major depression in patients with HIV/AIDS and substance abuse. AIDS Patient Care STDS, 21(12), 942-955.
5. Bouhnik, A.D., Preau, M., Vincent, E., Carrieri, M.P., Gallais, H., Lepeu, G., et al. (2005). Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antiviral Therapy, 10(1), 53-61.
6. Boyd, J.H., Weissman, M.M., Thompson, W.D., & Myers, J.K. (1982). Screening for depression in a community sample. Understanding the discrepancies between depression symptom and diagnostic scales. Archives of General Psychiatry, 39(10), 1195-1200.
7. Burack, J.H., Barrett, D.C., Stall, R.D., Chesney, M.A., Ekstrand, M.L., & Coates, T.J. (1993). Depressive symptoms and CD4 lymphocyte decline among HIVinfected men. JAMA, 270(21), 2568-2573.
8. Catz, S., Kelly, J.A., Bogart, L., Benotsch, E., & McAuliffe, T. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19, 124- 133.
9. Chesney, M.A., Ickovics, J.R., Chambers, D.B., Gifford, A.L., Neidig, J, Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care, 12, 255-266.
10. Ciesla, J.A., & Roberts, J.E. (2001). Meta-analysis ofthe relationship between HIV infection and risk for depressive disorders. American Journal of Psychiatry, 158(5), 725-730.
11. Cohen, R.A., Boland, R., Paul, R., Tashima, K.T., Schoenbaum, E.E., Celentano, D.D., et al. (2001). Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS, 15(3), 341-345.
12. Cook, J.A., Grey, D., Burke, J., Cohen, M.H., Gurtman, A.C., Richardson, J.L., et al. (2004). Depressive symptoms and AIDS-related mortality among a multisite cohort ofHIV-positive women. American Journal of Public Health, 94(7), 1133-1140.
13. Cruess, S., Antoni, M.H., Hayes, A., Penedo, F., Ironson, G., Fletcher, M.A., et al. (2002). Changes in mood and depressive symptoms and related change processes during cognitive-behavioral stress management in HIV infected men. Cognitive Therapy Research, 26, 373-392.
14. Fechner-Bates, S., Coyne, J.C., & Schwenk, T.L. (1994). The relationship ofself -reported distress to depressive disorders and other psychopathology. Journal of Consulting and Clinical Psychology, 62(3), 550-559.
15. Himelhoch, S., & Medoff, D.R. (2005). Efficacy of antidepressant medication among HIV-positive individuals with depression: A systematic review and meta-analysis. AIDS Patient Care STDS, 19(12), 813-822.
16. Hollon, S.D., DeRubeis, R.J., Shelton, R.C., Amsterdam, J.D., Salomon, R.M., O'Reardon, J.P., et al. (2005). Prevention ofrelapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417-422.
17. Huba, G.J., & Melchior, L.A. (1996). Staff of the Measurement Group, HRSA/HAB's SPNS Cooperative Agreement Steering Committee. Module 64: Self-Efficacy Form. Retrieved April 10, 2008, from www.The MeasurementGroup.com
18. Ickovics, J.R., Hamburger, M.E., Vlahov, D., Schoenbaum, E.E., Schuman, P., Boland, R.J., et al. (2001). Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA, 285(11), 1466-1474.
19. Johnson, J.G., Rabkin, J.G., Lipsitz, J.D., Williams, J.B., & Remien, R.H. (1999). Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: Findings ofa 3-year longitudinal study. Comparitive Psychiatry, 40(1), 31-34.
20. Knowlton, A.R., Latkin, C.A., Schroeder, J.R., Hoover, D.R., Ensminger, M., & Celentano, D.D. (2001). Longitudinal predictors ofdepressive symptoms among low income injection drug users. AIDS Care, 13(5), 549-559.
21. Kozal, M.J., Amico, K.R., Chiarella, J., Cornman, D., Fisher, W., Fisher, J., et al. (2005). HIV drug resistance and HIV transmission risk behaviors among active injection drug users. Journal of Acquired Immuno Deficiency Syndrome, 40(1), 106-109.
22. Kushel, M.B., Colfax, G., Ragland, K., Heineman, A., Palacio, H., & Bangsberg, D.R. (2006). Case management is associated with improved antiretroviral adherence and CD4- cell counts in homeless and marginally housed individuals with HIV infection. Clinical Infectious Disease, 43(2), 234-242.
23. Maru, D.S., Bruce, R.D., Walton, M., Mezger, J.A., Springer, S.A., Shield, D., et al. (2008). Initiation, adherence, and retention in a randomized controlled trial ofdirectly administered antiretroviral therapy. AIDS Behaviour, 12(2), 284-293.
24. Maru, D.S., Kozal, M.J., Bruce, R.D., Springer, S.A., & Altice, F.L. (2007). Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: Results from a randomized controlled trial. Journal of Acquired Immune Deficiency Syndrome, 46(5), 555-563.
25. Moatti, J.P., Carrieri, M.P., Spire, B., Gastault, J.A., Cassuto, J.P., & Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution ofbuprenorphine drug maintenance treatment. AIDS and Behavior, 14, 151-155.
26. Olatunji, B., Mimiaga, M., O'Cleirigh, C., & Safren, S. (2006). A review oftreatment studies ofdepression in HIV. Topics in HIV Medicine, 14(3), 112-124.
27. Perdue, T., Hagan, H., Thiede, H., & Valleroy, L. (2003). Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Education Preview, 15(1), 81-92.
28. Radloff, L.S. (1977). The CES-D scale: A self report depression scale for research in the general population. Applied Psychological Measurement, 1, 385-401.
29. Sacktor, N., Nakasujja, N., Skolasky, R., Robertson, K., Wong, M., Musisi, S., et al. (2006). Antiretroviral therapy improves cognitive impairment in HIV- individuals in sub-Saharan Africa. Neurology, 67(2), 311-314.
30. Skinner, H.A. (1982). The drug abuse screening test. Addict Behaviour, 7(4), 363-371.
31. Smith-Rohrberg, D., & Altice, F.L. (2006). Randomized, controlled trials ofdirectly administered antiretroviral therapy for HIV-infected patients: Questions about study population and analytical approach. Clinical Infectious Diseases, 43(9), 1221-1222; author reply 1222-1223.
32. Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R.D., & Altice, F.L. (2006). Impact ofenhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. Journal of Acquired Immuno Deficiency Syndrome Human Reterovirology, 43(Suppl. 1), 48-53.
33. Suarez, S., Baril, L., Stankoff, B., Khellaf, M., Dubois, B., Lubetzki, C., et al. (2001). Outcome ofpatients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS, 15(2), 195-200.